Skip to main content

Table 1 Adverse event analysis

From: Hyaluronic acid injection therapy for osteoarthritis of the knee: concordant efficacy and conflicting serious adverse events in two systematic reviews

AE category Number of studies Number of events, HA group Sample size, HA group Number of events, placebo group Sample size, placebo group Relative risk 95 % confidence interval
All serious AEs (combined joint and othera) 8 27 1056 16 1017 1.39 (0.78, 2.47)
Serious AEs, joint (e.g., synovitis) 5 10 442 8 447 1.25 (0.53, 2.94)
Serious AEs, other (e.g., herpes zoster) 6 17 614 8 570 1.52 (0.70, 3.26)
All non-serious AEs (combined joint, local non-joint, and other) 10 415 1645 375 1564 1.03 (0.93, 1.15)
Non-serious AEs, joint (e.g., pain) 7 121 559 97 518 1.15 (0.91, 1.43)
Non-serious AEs, local non-joint (e.g., erythema) 6 98 492 79 493 1.26 (0.99, 1.60)
Non-serious AEs, other (e.g., headache) 6 196 594 199 553 0.89 (0.78, 1.03)
  1. Our review finds no significant risk of adverse events (NSAEs) or serious adverse events (SAEs) associated with hyaluronic acid (HA) injections in knee osteoarthritis (confidence intervals cross 1; italicized rows). Subgroup analysis by AE category (joint, other, local non-jointa) also found no significant risk of NSAEs or SAEs (confidence intervals cross 1; plain text rows)
  2. aNo studies reported local non-joint SAEs